Neonatal outcomes associated with late preterm betamethasone administration in women with pregestational diabetes

Abstract

Antenatal corticosteroids improve neonatal outcomes in the late preterm period (34 + 0 and 36 + 6 weeks gestation),1 and this practice has been widely adopted in the United States. While women with pregestational diabetes (PGDM) are at particularly high risk for adverse neonatal outcomes,2 they have been excluded from previous clinical trials.3 This study aimed to examine neonatal outcomes among women with PGDM who received betamethasone (BMZ group) in the late preterm period compared with non-exposed women (control group).